A new trading day began on Friday, with Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) stock price up 7.43% from the previous day of trading, before settling in for the closing price of $1.48. ZNTL’s price has ranged from $1.01 to $5.44 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -12.89% over the last five years. Meanwhile, its annual earnings per share averaged 7.24%. With a float of $57.22 million, this company’s outstanding shares have now reached $72.14 million.
The firm has a total of 166 workers. Let’s measure their productivity. In terms of profitability, gross margin is 97.23%, operating margin of -681.04%, and the pretax margin is -606.79%.
Zentalis Pharmaceuticals Inc (ZNTL) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Zentalis Pharmaceuticals Inc is 21.66%, while institutional ownership is 73.26%. The most recent insider transaction that took place on Apr 30 ’25, was worth 29,373. In this transaction Director of this company bought 21,000 shares at a rate of $1.40, taking the stock ownership to the 281,192 shares. Before that another transaction happened on Feb 06 ’25, when Company’s Chief Medical Officer bought 20,000 for $2.28, making the entire transaction worth $45,656. This insider now owns 36,629 shares in total.
Zentalis Pharmaceuticals Inc (ZNTL) Earnings and Forecasts
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.56 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.48 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.24% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.39% during the next five years compared to -12.89% drop over the previous five years of trading.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Trading Performance Indicators
Here are Zentalis Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.99. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.28, a number that is poised to hit -0.53 in the next quarter and is forecasted to reach -2.07 in one year’s time.
Technical Analysis of Zentalis Pharmaceuticals Inc (ZNTL)
Analysing the last 5-days average volume posted by the [Zentalis Pharmaceuticals Inc, ZNTL], we can find that recorded value of 0.79 million was lower than the volume posted last year of 1.24 million. As of the previous 9 days, the stock’s Stochastic %D was 70.88%.
During the past 100 days, Zentalis Pharmaceuticals Inc’s (ZNTL) raw stochastic average was set at 57.71%, which indicates a significant decrease from 71.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0945 in the past 14 days, which was lower than the 0.1067 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3868, while its 200-day Moving Average is $2.0370. Now, the first resistance to watch is $1.6929. This is followed by the second major resistance level at $1.7959. The third major resistance level sits at $1.8923. If the price goes on to break the first support level at $1.4935, it is likely to go to the next support level at $1.3971. Should the price break the second support level, the third support level stands at $1.2941.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Key Stats
With a market capitalization of 114.70 million, the company has a total of 72,135K Shares Outstanding. Currently, annual sales are 67,430 K while annual income is -165,840 K. The company’s previous quarter sales were 0 K while its latest quarter income was -48,280 K.
